MoreTrials

MoreTrials: A public campaign to make it much easier to do randomised trials

You are here: Home / News Post / What might clinical trials look like after Covid-19? A talk by Rob Califf

May 06 2020

What might clinical trials look like after Covid-19? A talk by Rob Califf

Professor Rob Califf, Duke and former commissioner at the FDA recently outlined his thoughts on what the clinical trial space might look like after the Covid-19 pandemic. In the talk, Rob outlines the problems with doing large-scale trials and sets an optimistic tone on what might emerge after the pandemic. You can watch the full talk here.

Below are a few highlights of the talk:

“If we are going to treat people well and optimise their chances of a good health outcome, we need to have evidence that is high-quality that we can depend on. Otherwise, we are suffering from ‘eminence based medicine’ where doctors somehow think they know what the best thing is despite the absence of evidence.”

“In cardiovascular disease only 8.5% of major recommendations in clinical practice guidelines are based on high-quality evidence.”

“There are two options following the Covid crisis. We can either make the changes we need now to deal with the emergency hoping we can revert back to the ‘good old days’, or we can take the path of learning from what is happening now and implementing changes in the system that are permanent and move us to much more quickly to the system that is envisioned but not yet enacted.”

Rob Califf

 

“Clinicians involved in pragmatic trials don’t all have to complete GCP training”

Anonymous

 

“The value of randomization is undermined by poorly designed and underpowered trials”

Dr Fauci

 

The talk featured the RECOVERY trial run across the UK which is evaluating a number of treatments for Covid-19. In a recent talk for CTTI – which you can find here (the talk starts at 1:02), Professor Martin Landray presented some of the key findings that have already emerged from this ground breaking trial:

  • Simple 2-page consent form
  • Single ethics committee approval
  • Simple 26 page protocol (which you can download here)
  • 3 days to go from first draft to final protocol
  • 5 days to get ethics committee approval
  • 9 days to go from first draft protocol to first patient recruited
  • 15 days to go from first patient to 1,000 patients recruited
  • To date, over 7,000 patients randomised from over 160 hospitals

None of us know yet how things will be at the end of the pandemic. That said, perhaps, trials like RECOVERY – focusing on the fundamental principles to answer a question reliably and keep patients’ (and staff) safe – are giving us a glimpse of how trials might get done in the future.

Print Friendly

Written by Tim Sprosen · Categorized: News Post

Search Form

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

A public campaign for more, better, randomised trials

Pages

  • About us
  • The Problem
    • ICH
    • ICH-GCP guideline
    • Response from ICH
    • ICH’s GCP Renovation Project
    • Stories to Highlight the Problems
  • The Solution
    • The Plan: Joint Funder Initiative
    • Developing the New-GCP
  • News
  • The unique value of randomised trials
    • Quotes
    • Illustration
    • The wider context
    • CTTI: Making things better
    • Stories of Trials That Matter
  • Supporters: Organisations
  • Supporters: Trialists
    • AllTrials
  • Videos
  • Join us
  • Contact us

Join over 260 trialists from around 35 countries

Search Form

  • Google+
  • Twitter

© 2021 Moretrials.net · Rainmaker Platform